Chemoprevention gene therapy (CGT) of pancreatic cancer using perillyl alcohol and a novel chimeric serotype Cancer Terminator Virus

Current Molecular Medicine

Volumn 14, Issue 1, 2014, Pages 125-140

  Sarkar, S ^a   Azab, B ^a   Quinn, B A ^a   Shen, X ^a   Dent, P ^a   Klibanov, A L ^b   Emdad, L ^a,b   Das, S K ^a,b   Sarkar, D ^a,b   Fisher, P B ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Cancer terminator virus expressing mda 7 IL 24 (CTV M7); Chemoprevention gene therapy (CGT); Endoplasmic reticulum stress (ER stress); Melanoma differentiation associated gene 7 interleukin 24 (mda 7 IL 24); Microbubble (MB); Pancreatic ductal adenocarcinoma (PDAC); Perillyl alcohol (POH); Ultrasound targeted microbubble destruction (UTMD)

Indexed keywords

AD 5 3 PEG E1A MDA 7; ANTINEOPLASTIC AGENT; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; FLUOROURACIL; GAMMA INTERFERON; GEMCITABINE; INTERLEUKIN 24; INTERLEUKIN 6; PERILLYL ALCOHOL; PROTEIN BCL 2; PROTEIN BCL XL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CHEMOPREVENTION GENE THERAPY; CONTROLLED STUDY; ENDOPLASMIC RETICULUM STRESS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENE THERAPY; HUMAN; HUMAN CELL; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PANCREAS CANCER; PLASMID; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; SCORING SYSTEM; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; CELL DIFFERENTIATION; CELL VIABILITY ASSAY; CHEMOPROPHYLAXIS; MTT ASSAY; PANCREAS ADENOCARCINOMA; TUMOR GROWTH; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; CELL LINE, TUMOR; CELL SURVIVAL; CHEMOPREVENTION; DISEASE MODELS, ANIMAL; ENDOPLASMIC RETICULUM STRESS; GENE EXPRESSION; GENETIC THERAPY; GENETIC VECTORS; HUMANS; INTERLEUKINS; MICE; MONOTERPENES; ORGAN SPECIFICITY; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; REACTIVE OXYGEN SPECIES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84891849832     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/1566524013666131118110827     Document Type: Article

References (75)

1. American Cancer Society. Cancer Facts and Figures 2012. Atlanta, Ga: American Cancer Society Inc. 2012.
2. Sarkar S, Azab BM, Das SK, et al. Chemoprevention gene therapy (CGT): novel combinatorial approach for preventing and treating pancreatic cancer. Curr Mol Med 2013; 13: 1140-59.
3. Garber K. China approves world's first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst 2006; 98: 298-300.
4. Su ZZ, Sarkar D, Emdad L, et al. Targeting gene expression selectively in cancer cells by using the progression-elevated gene-3 promoter. Proc Natl Acad Sci U S A 2005; 102: 1059-64.
5. Su ZZ, Shi Y, Fisher PB. Subtraction hybridization identifies a transformation progression-associated gene PEG-3 with sequence homology to a growth arrest and DNA damageinducible gene. Proc Natl Acad Sci U S A 1997; 94: 9125-30.
6. Sarkar D, Su ZZ, Park ES, et al. A cancer terminator virus eradicates both primary and distant human melanomas. Cancer Gene Ther 2008; 15: 293-302.
7. Sarkar D, Su ZZ, Vozhilla N, Park ES, Gupta P, Fisher PB. Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice. Proc Natl Acad Sci U S A 2005; 102: 14034-9.
8. Sauane M, Gopalkrishnan RV, Sarkar D, et al. MDA-7/IL-24: novel cancer growth suppressing and apoptosis inducing cytokine. Cytokine Growth Factor Rev 2003; 14: 35-51.
9. Sauane M, Su ZZ, Gupta P, et al. Autocrine regulation of mda-7/IL-24 mediates cancer-specific apoptosis. Proc Natl Acad Sci U S A 2008; 105: 9763-8.
10. Dash R, Bhutia SK, Azab B, et al. mda-7/IL-24: a unique member of the IL-10 gene family promoting cancer-targeted toxicity. Cytokine Growth Factor Rev 2010; 21: 381-91.
11. Sarkar D, Su ZZ, Vozhilla N, et al. Targeted virus replication plus immunotherapy eradicates primary and distant pancreatic tumors in nude mice. Cancer Res 2005; 65: 9056-63.
12. Pearson AS, Koch PE, Atkinson N, et al. Factors limiting adenovirus-mediated gene transfer into human lung and pancreatic cancer cell lines. Clin Cancer Res 1999; 5: 4208-13.
13. Dash R, Dmitriev I, Su ZZ, et al. Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) improves therapeutic efficacy in low CAR prostate cancer cells. Cancer Gene Ther 2010; 17: 447-56.
14. Dash R, Azab B, Quinn BA, et al. Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity. Proc Natl Acad Sci U S A 2011; 108: 8785-90.
15. Su Z, Lebedeva IV, Gopalkrishnan RV, et al. A combinatorial approach for selectively inducing programmed cell death in human pancreatic cancer cells. Proc Natl Acad Sci U S A 2001; 98: 10332-7.
16. Lebedeva IV, Emdad L, Su ZZ, et al. mda-7/IL-24, novel anticancer cytokine: focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience (Review). Int J Oncol 2007; 31: 985-1007.
17. Emdad L, Sarkar D, Lebedeva IV, et al. Ionizing radiation enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human ovarian cancer. J Cell Physiol 2006; 208: 298-306.
18. McKenzie T, Liu Y, Fanale M, Swisher SG, Chada S, Hunt KK. Combination therapy of Ad-mda7 and trastuzumab increases cell death in Her-2/neu-overexpressing breast cancer cells. Surgery 2004; 136: 437-42.
19. Jiang H, Lin JJ, Su ZZ, Goldstein NI, Fisher PB. Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. Oncogene 1995; 11: 2477-86.
20. Sarkar D, Su ZZ, Lebedeva IV, et al. mda-7 (IL-24) Mediates selective apoptosis in human melanoma cells by inducing the coordinated overexpression of the GADD family of genes by means of p38 MAPK. Proc Natl Acad Sci U S A 2002; 99: 10054-9.
21. Das SK, Sarkar S, Dash R, et al. Chapter One---Cancer terminator viruses and approaches for enhancing therapeutic outcomes. Adv Cancer Res 2012; 115: 1-38.
22. Eager R, Harle L, Nemunaitis J. Ad-MDA-7; INGN 241: a review of preclinical and clinical experience. Expert Opin Biol Ther 2008; 8: 1633-43.
23. Tong AW, Nemunaitis J, Su D, et al. Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients. Mol Ther 2005; 11: 160-72.
24. Fisher PB, Gopalkrishnan RV, Chada S, et al. mda-7/IL-24, a novel cancer selective apoptosis inducing cytokine gene: from the laboratory into the clinic. Cancer Biol Ther 2003; 2: S23-37.
25. Fisher PB, Sarkar D, Lebedeva IV, et al. Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24): novel gene therapeutic for metastatic melanoma. Toxicol Appl Pharmacol 2007; 224: 300-7.
26. Cunningham CC, Chada S, Merritt JA, et al. Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study. Mol Ther 2005; 11: 149-59.
27. Hamid O, Varterasian ML, Wadler S, et al. Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 1498-504.
28. Muruve DA. The innate immune response to adenovirus vectors. Hum Gene Ther 2004; 15: 1157-66.
29. Greco A, Di Benedetto A, Howard CM, et al. Eradication of therapy-resistant human prostate tumors using an ultrasound-guided site-specific cancer terminator virus delivery approach. Mol Ther 2010; 18: 295-306.
30. Dash R, Azab B, Shen XN, et al. Developing an effective gene therapy for prostate cancer: New technologies with potential to translate from the laboratory into the clinic. Discov Med 2011; 11: 46-56.
31. Azab B, Dash R, Das SK, et al. Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) in combination with the Apogossypol derivative BI-97C1 (Sabutoclax) improves therapeutic efficacy in low CAR colorectal cancer cells. J Cell Physiol 2012; 227: 2145-53.
32. Lebedeva IV, Su ZZ, Vozhilla N, et al. Mechanism of in vitro pancreatic cancer cell growth inhibition by melanoma differentiation-associated gene-7/interleukin-24 and perillyl alcohol. Cancer Res 2008; 68: 7439-47.
33. Lebedeva IV, Su ZZ, Sarkar D, et al. Induction of reactive oxygen species renders mutant and wild-type K-ras pancreatic carcinoma cells susceptible to Ad.mda-7-induced apoptosis. Oncogene 2005; 24: 585-96.
34. Bell EL, Klimova TA, Eisenbart J, Schumacker PT, Chandel NS. Mitochondrial reactive oxygen species trigger hypoxiainducible factor-dependent extension of the replicative life span during hypoxia. Mol Cell Biol 2007; 27: 5737-45.
35. Gerasimovskaya EV, Tucker DA, Stenmark KR. Activation of phosphatidylinositol 3-kinase, Akt, and mammalian target of rapamycin is necessary for hypoxia-induced pulmonary artery adventitial fibroblast proliferation. J Appl Physiol 2005; 98: 722-31.
36. Huang C, Li J, Ke Q, et al. Ultraviolet-induced phosphorylation of p70(S6K) at Thr(389) and Thr(421)/Ser(424) involves hydrogen peroxide and mammalian target of rapamycin but not Akt and atypical protein kinase C. Cancer Res 2002; 62: 5689-97.
37. Bae GU, Seo DW, Kwon HK, et al. Hydrogen peroxide activates p70(S6k) signaling pathway. J Biol Chem 1999; 274: 32596-602.
38. Lebedeva IV, Su ZZ, Vozhilla N, et al. Chemoprevention by perillyl alcohol coupled with viral gene therapy reduces pancreatic cancer pathogenesis. Mol Cancer Ther 2008; 7: 2042-50.
39. Lebedeva IV, Sarkar D, Su ZZ, et al. Bcl-2 and Bcl-x(L) differentially protect human prostate cancer cells from induction of apoptosis by melanoma differentiation associated gene-7, mda-7/IL-24. Oncogene 2003; 22: 8758-73.
40. Webb JL. Effect of more than one inhibitor. Enzyme and Metabolic Inhibitors. New York: Academic Press 1963; p. 66-79.
41. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58: 621-81.
42. Howard CM, Forsberg F, Minimo C, Liu JB, Merton DA, Claudio PP. Ultrasound guided site specific gene delivery system using adenoviral vectors and commercial ultrasound contrast agents. J Cell Physiol 2006; 209: 413-21.
43. Ripple GH, Gould MN, Stewart JA, et al. Phase I clinical trial of perillyl alcohol administered daily. Clin Cancer Res 1998; 4: 1159-64.
44. Hudes GR, Szarka CE, Adams A, et al. Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies. Clin Cancer Res 2000; 6: 3071-80.
45. da Fonseca CO, Simao M, Lins IR, Caetano RO, Futuro D, Quirico-Santos T. Efficacy of monoterpene perillyl alcohol upon survival rate of patients with recurrent glioblastoma. J Cancer Res Clin Oncol 2011; 137: 287-93.
46. McGuire KA, Barlan AU, Griffin TM, Wiethoff CM. Adenovirus type 5 rupture of lysosomes leads to cathepsin B-dependent mitochondrial stress and production of reactive oxygen species. J Virol 2011; 85: 10806-13.
47. Gupta P, Walter MR, Su ZZ, et al. BiP/GRP78 is an intracellular target for MDA-7/IL-24 induction of cancerspecific apoptosis. Cancer Res 2006; 66: 8182-91.
48. Wu J, Kaufman RJ. From acute ER stress to physiological roles of the Unfolded Protein Response. Cell Death Differ 2006; 13: 374-84.
49. Pataer A, Hu W, Xiaolin L, et al. Adenoviral endoplasmic reticulum-targeted mda-7/interleukin-24 vector enhances human cancer cell killing. Mol Cancer Ther 2008; 7: 2528-35.
50. Hinz S, Trauzold A, Boenicke L, et al. Bcl-XL protects pancreatic adenocarcinoma cells against CD95-and TRAILreceptor-mediated apoptosis. Oncogene 2000; 19: 5477-86.
51. Campani D, Esposito I, Boggi U, et al. Bcl-2 expression in pancreas development and pancreatic cancer progression. J Pathol 2001; 194: 444-50.
52. Evans JD, Cornford PA, Dodson A, Greenhalf W, Foster CS, Neoptolemos JP. Detailed tissue expression of bcl-2, bax, bak and bcl-x in the normal human pancreas and in chronic pancreatitis, ampullary and pancreatic ductal adenocarcinomas. Pancreatology 2001; 1: 254-62.
53. Bai J, Sui J, Demirjian A, Vollmer CM, Jr., Marasco W, Callery MP. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro. Cancer Res 2005; 65: 2344-52.
54. Carrington EM, McKenzie MD, Jansen E, et al. Islet betacells deficient in Bcl-xL develop but are abnormally sensitive to apoptotic stimuli. Diabetes 2009; 58: 2316-23.
55. Morishima N, Nakanishi K, Tsuchiya K, Shibata T, Seiwa E. Translocation of Bim to the endoplasmic reticulum (ER) mediates ER stress signaling for activation of caspase-12 during ER stress-induced apoptosis. J Biol Chem 2004; 279: 50375-81.
56. Zhou YP, Pena JC, Roe MW, et al. Overexpression of Bclx(L) in beta-cells prevents cell death but impairs mitochondrial signal for insulin secretion. Am J Physiol Endocrinol Metab 2000; 278: E340-51.
57. Szegezdi E, Logue SE, Gorman AM, Samali A. Mediators of endoplasmic reticulum stress-induced apoptosis. EMBO Rep 2006; 7: 880-5.
58. Curiel DT, Fisher PB. Advances in Cancer Research: Applications of viruses for cancer therapy, 1st ed. 2012; p. 1-326.
59. Jiang H, Wang Z, Serra D, Frank MM, Amalfitano A. Recombinant adenovirus vectors activate the alternative complement pathway, leading to the binding of human complement protein C3 independent of anti-ad antibodies. Mol Ther 2004; 10: 1140-2.
60. Boucher MJ, Morisset J, Vachon PH, Reed JC, Laine J, Rivard N. MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells. J Cell Biochem 2000; 79: 355-69.
61. Greten FR, Weber CK, Greten TF, et al. Stat3 and NFkappaB activation prevents apoptosis in pancreatic carcinogenesis. Gastroenterology 2002; 123: 2052-63.
62. Hamacher R, Schmid RM, Saur D, Schneider G. Apoptotic pathways in pancreatic ductal adenocarcinoma. Mol Cancer 2008; 7: 64.
63. Shi X, Liu S, Kleeff J, Friess H, Buchler MW. Acquired resistance of pancreatic cancer cells towards 5-Fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncology 2002; 62: 354-62.
64. Friess H, Lu Z, Andren-Sandberg A, et al. Moderate activation of the apoptosis inhibitor bcl-xL worsens the prognosis in pancreatic cancer. Ann Surg 1998; 228: 780-7.
65. Westphal S, Kalthoff H. Apoptosis: targets in pancreatic cancer. Mol Cancer 2003; 2: 6.
66. Hamed HA, Yacoub A, Park MA, et al. Inhibition of multiple protective signaling pathways and Ad.5/3 delivery enhances mda-7/IL-24 therapy of malignant glioma. Mol Ther 2010; 18: 1130-42.
67. Chada S, Mhashilkar AM, Ramesh R, et al. Bystander activity of Ad-mda7: human MDA-7 protein kills melanoma cells via an IL-20 receptor-dependent but STAT3-independent mechanism. Mol Ther 2004; 10: 1085-95.
68. Chung BH, Lee HY, Lee JS, Young CY. Perillyl alcohol inhibits the expression and function of the androgen receptor in human prostate cancer cells. Cancer Lett 2006; 236: 222-8.
69. Bardon S, Foussard V, Fournel S, Loubat A. Monoterpenes inhibit proliferation of human colon cancer cells by modulating cell cycle-related protein expression. Cancer Lett 2002; 181: 187-94.
70. Stark MJ, Burke YD, McKinzie JH, Ayoubi AS, Crowell PL. Chemotherapy of pancreatic cancer with the monoterpene perillyl alcohol. Cancer Lett 1995; 96: 15-21.
71. Liu G, Oettel K, Bailey H, et al. Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer. Invest New Drugs 2003; 21: 367-72.
72. Bailey HH, Attia S, Love RR, et al. Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer. Cancer Chemother Pharmacol 2008; 62: 149-57.
73. Meadows SM, Mulkerin D, Berlin J, et al. Phase II trial of perillyl alcohol in patients with metastatic colorectal cancer. Int J Gastrointest Cancer 2002; 32: 125-8.
74. Rajesh D, Stenzel RA, Howard SP. Perillyl alcohol as a radio-/chemosensitizer in malignant glioma. J Biol Chem 2003; 278: 35968-78.
75. da Fonseca CO, Linden R, Futuro D, Gattass CR, Quirico-Santos T. Ras pathway activation in gliomas: a strategic target for intranasal administration of perillyl alcohol. Arch Immunol Ther Exp (Warsz) 2008; 56: 267-76.